Summit Therapeutics Inc. had data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, presented at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen, Denmark. Data for HARMONi was generated and analyzed by Summit and for HARMONi-2 by collaboration and licensing partner, Akeso Inc. Summit began its clinical development of ivonescimab in NSCLC, commencing enrollment in 2023 in two multiregional Phase III clinical trials, HARMONi and HARMONi-3. In 2025, the Company began enrolling patients in HARMONi-7. Summit expanded its Phase III clinical development program into CRC in the fourth quarter of 2025 by initiating enrollment in HARMONi-GI3. There are currently 15 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, four of which are Summit-sponsored global studies, one of which is a multiregional study sponsored by a cooperative group, and ten of which are being or have been conducted in China by Akeso.